Hikma launches denosumab biosimilars in USA
UK headquartered Hikma Pharmaceuticals (LSE: HIK), along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc, have announced the launch of Enoby (denosumab-qbde) and Xtrenbo (denosumab-qbde), biosimilar products referencing US biotech major Amgen’s (Nasdaq: AMGN) Prolia and Xgeva respectively.
Hikma and Hungary’s Gedeon Richter (RICHT: HB) entered into a license and commercialization agreement for Enoby and Xtrenbo, originally known as RGB-14, in 2021. Under the terms of this agreement, Richter is responsible for the manufacture of the products, and Hikma is responsible for exclusive commercialization in the US.
Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer that has spread to the bone, and treating unresectable giant cell tumor of the bone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
| Headless Content Management with Blaze